ライフサイエンスコーパス: interim analysis

1 d points, including overall survival (at the interim analysis).

2 vival was not reached in either group at the interim analysis.

3 of 7651 people were included in the planned interim analysis.

4 icacy thresholds were not met at the planned interim analysis.

5 minated based on the results of this planned interim analysis.

6 concluded early for futility after a planned interim analysis.

7 s terminated for futility after a preplanned interim analysis.

8 nded by the safety committee after a planned interim analysis.

9 pped the study for futility after the second interim analysis.

10 We report results from the preplanned interim analysis.

11 This was a prespecified interim analysis.

12 n of the trial after the second prespecified interim analysis.

13 for futility in April, 2011, after a planned interim analysis.

14 The study was stopped after an interim analysis.

15 or futility at the time of the first planned interim analysis.

16 this group, and the study was stopped at the interim analysis.

17 ed O'Brien-Fleming boundary (.00116) for the interim analysis.

18 onsor stopped the trial after a prespecified interim analysis.

19 The trial was stopped for futility at interim analysis.

20 ignificant treatment benefit in one group at interim analysis.

21 patients enrolled after results of a planned interim analysis.

22 ped because of the results of a prespecified interim analysis.

23 n based on efficacy or futility at a planned interim analysis.

24 respecified futility boundaries at the first interim analysis.

25 Data reported are from the interim analysis.

26 and no PSA declines 50% were observed at the interim analysis.

27 een reported, triggering the first scheduled interim analysis.

28 data from > or =8 weeks were included in the interim analysis.

29 The study was terminated at the first interim analysis.

30 fering open-label emtricitabine based on the interim analysis.

31 led into the study and are presented in this interim analysis.

32 imary end point was tested in a prespecified interim analysis.

33 groups for this prospectively planned second interim analysis.

34 urrence of 2 deaths in the placebo arm in an interim analysis.

35 than with bortezomib and dexamethasone in an interim analysis.

36 tical comparisons were done post hoc in this interim analysis.

37 test for paired binary data in a preplanned interim analysis.

38 from this study based on an unplanned second interim analysis.

39 s terminated for futility after a preplanned interim analysis.

40 nts and was discontinued for futility at the interim analysis.

41 275) were closed for futility at the second interim analysis.

42 nts after washout; after 12 weeks, we did an interim analysis.

43 We report on a planned interim analysis.

44 ed over from placebo to pertuzumab after the interim analysis.

45 At the time of the interim analysis, 142 participants were evaluable.

46 At the first interim analysis, 22 of 40 patients in the lithium group

47 At the time of interim analysis, 286 (21%) of 1343 enrolled patients ha

48 nation for futility at the second preplanned interim analysis (382 PFS events).

49 en the study was stopped after a pre-planned interim analysis, 396 patients were randomly assigned (1

50 In this 5-year interim analysis, 4821 patients were enrolled.

51 At interim analysis, 50 patients were enrolled at a single

52 ted among the 1,261 patients included in the interim analysis (643 rPAF-AH and 618 placebo), but did

53 At the time of the interim analysis, 745 (99%) of the planned 748 patients

54 At the prespecified interim analysis, 82 participants progressed to CNV, 51

55 In the interim analysis, a significantly higher percentage of i

56 We did a planned interim analysis after 219 (41%) deaths had occurred to

57 free survival at day 56 was met at a planned interim analysis after 235 patients (of 372) were enroll

58 The trial was stopped upon predefined interim analysis after 30 patients because of significan

59 the prespecified futility boundary at second interim analysis after 340 deaths, but survival follow-u

60 was designed to enroll 100 patients with an interim analysis after 50 patients.

61 analysis was planned after 196 deaths and an interim analysis after 98 deaths.

62 ter 378 expected events, with a confidential interim analysis after approximately 87 events (25% inte

63 stopped for futility at the first scheduled interim analysis after enrollment of 300 patients, of wh

64 Interim analysis after inclusion of 53 patients (50%) wi

65 The study was terminated at the interim analysis after randomizing 30 patients.

66 The trial was stopped in 2007 at the second interim analysis after treatment resulted in a reduction

67 We report the results of a prespecified interim analysis after two-thirds of the planned study e

68 val, with an overall survival benefit at the interim analysis, among patients with newly diagnosed mu

69 g committee reviewed the data at the planned interim analysis and declared overall survival superiori

70 ly improved progression-free survival at the interim analysis and had a favorable risk-benefit profil

71 atening serious adverse events at the fourth interim analysis and included 182 patients.

72 due to futility for efficacy at an unplanned interim analysis and increased rates of safety end point

73 Study results at an interim analysis and lack of efficacy in another phase I

74 mg; no PSA declines 50% were observed at the interim analysis and recruitment was stopped.

75 11 (last patient visit July, 2011), after an interim analysis, and suggested a change in primary outc

76 nrolled before the study was closed early at interim analysis (arm A, n = 136; arm B, n = 134).

77 However, at the second interim analysis at 1 year, overall survival was 96% (95

78 t 2 years; this paper reports a prespecified interim analysis at 1 year.

79 After interim analysis at 50% enrollment, the Data Safety Moni

80 The study was stopped after a planned interim analysis at the time of 520 deaths.

81 A two-stage design with an interim analysis based on 852 patients after 53.3 months

82 The study was stopped at the first interim analysis because criterion for futility was met

83 Enrollment was stopped after the first interim analysis because of a significantly lower freque

84 y was prematurely terminated after the first interim analysis because of inferiority of the transulna

85 ed termination of the study after the second interim analysis because of safety concerns and low effi

86 Recruitment was stopped after the second interim analysis because of safety concerns.

87 trial was closed after the second scheduled interim analysis because of slow accrual and the end of

88 The trial was stopped for futility after the interim analysis, because the results in the experimenta

89 f improvement did not cross the prespecified interim analysis boundary of P=0.000019.

90 e unmasking took place at age 2 years for an interim analysis, but participants and nearly all invest

91 After review of the interim analysis by an independent data and safety monit

92 The trial was stopped after an interim analysis by an independent data safety monitorin

93 Enrollment was stopped when an interim analysis concluded that the trial would be unlik

94 An unplanned interim analysis conducted in April 2005 rejected the al

95 vival in both males and females, based on an interim analysis conducted near the median survival poin

96 A prespecified interim analysis, conducted when 314 deaths had occurred

97 The study was stopped after a planned interim analysis, conducted when 540 deaths had been rep

98 f an overall survival benefit was seen in an interim analysis; confirmation will be required in the p

99 Before an interim analysis confirmed acceptable safety for IFL/BV,

100 ), and median overall survival at the second interim analysis crossed the stopping boundary for effic

101 of overall survival was met at a preplanned interim analysis; data cutoff was on July 21, 2011.

102 The study closed in December 1999 after an interim analysis demonstrated little likelihood of CIFU

103 The trial was closed early after an interim analysis demonstrated that the projected 37.5% i

104 167 patients were enrolled when a scheduled interim analysis detected a venous thrombosis rate that

105 The pre-planned interim analysis done by intention to treat was done aft

106 and July 9, 2014, and assessed through to an interim analysis done on Jan 26, 2016.

107 early because the trial results crossed the interim analysis efficacy boundary for recurrence-free s

108 Study enrollment was closed after an interim analysis estimated a 5-year event-free survival

109 This planned interim analysis evaluated objective response rate (RR),

110 Positive interim analysis findings from four large adjuvant trial

111 futility boundary was crossed at the planned interim analysis for combination therapy compared with l

112 8 years, the trial was stopped at the second interim analysis for futility regarding RFS (hazard rati

113 Schedule B was closed at interim analysis for inferior efficacy.

114 In the interim analysis for overall survival and final analysis

115 This article reports the interim analysis for recurrence-free survival (RFS), whi

116 Interim analysis from the community-based sentinel surve

117 the mean follow-up was only 3.75 years, our interim analysis had limited statistical power to detect

118 Interim analysis halfway through the trial had a Lan-DeM

119 This three-year (interim) analysis has indicated a trend towards better g

120 0.4) in the bortezomib group at a preplanned interim analysis (hazard ratio [HR] 0.53 [95% CI 0.44-0.

121 At the interim analysis, HRQoL was assessed with the Functional

122 At an interim analysis in January, 2009, the independent data

123 The study was stopped early at the planned interim analysis in July, 2015, because the study met it

124 The first interim analysis in October 2009, with 46% of the projec

125 In a prespecified interim analysis in participants with baseline Ad5 antib

126 roved overall survival (OS) after the second interim analysis (in 2012) of 271 deaths in the Gynecolo

127 This planned interim analysis included 138 treated patients with FA-r

128 The interim analysis included 210 patients randomized to TTF

129 The evaluable data set for the interim analysis included 28 patients in the CP-316,311

130 This interim analysis included 90 patients who received idaru

131 At a prespecified interim analysis, including 212 primary end point events

132 The results of this interim analysis indicate that rVSV-ZEBOV might be highl

133 to study medication, 34.7 weeks) because an interim analysis indicated a low likelihood of showing e

134 The results of the second interim analysis indicated a significant difference in e

135 This 1-year interim analysis indicates that a decreasing dosage of t

136 An interim analysis is scheduled after the first 30 patient

137 A scheduled interim analysis led to a stopping recommendation becaus

138 For the 25% interim analysis, MACE occurred in 59 placebo-treated pa

139 e primary endpoint was met at the preplanned interim analysis (March 10, 2015).

140 At the first preplanned interim analysis (March, 2016), the independent data mon

141 Because interim analysis may not address longer-term outcomes of

142 At the time of the second prespecified interim analysis, median follow-up was 22.2 months (IQR

143 At the interim analysis, median progression-free survival was 6

144 The trial was stopped after the interim analysis met the criteria for early stopping.

145 The study was terminated when the second interim analysis met the prespecified futility stopping

146 nitoring board because the second preplanned interim analysis met the prespecified stopping rule for

147 At an interim analysis, more deaths were noted in the ASCENT a

148 Arm C was closed for futility at the first interim analysis (n = 241), and arm A (n = 267) and arm

149 Study was terminated after interim analysis (n = 98); 90 patients were available fo

150 Results of the preplanned interim analysis (n=15 in each group) of the primary end

151 At the first scheduled interim analysis, non-inferiority was shown and the spon

152 At the first interim analysis, nonefficacy criteria were met.

153 An event-triggered interim analysis occurred after 272 events on the refere

154 At the pre-planned interim analysis (Oct 14, 2013), the IDMC selected trast

155 In this interim analysis of 188 patients, changes in fasting ser

156 At the planned interim analysis of 22 patients on PCF, grade 3 or highe

157 In this interim analysis of 315 patients with glioblastoma who h

158 Anderson Cancer Center, and before a planned interim analysis of 44 events.

159 After interim analysis of 48 patients, the study was closed fo

160 The trial was halted after a planned interim analysis of 48% of predicted events (246/515) oc

161 Panitumumab was discontinued after a planned interim analysis of 812 oxaliplatin patients showed wors

162 We found the association in an interim analysis of a genome-wide nonsynonymous SNP (nsS

163 s over age 65 years who received surgery and interim analysis of a larger trial.

164 This 1-year interim analysis of a long-term, prospective, randomized

165 In this interim analysis of a multicentre, open-label, non-rando

166 We previously reported the interim analysis of a multicentre, randomised, double-bl

167 We did this interim analysis of a non-randomised, phase 2 trial at 2

168 d pain and functional status in a preplanned interim analysis of a phase 3 trial.

169 wever, trial sequential analyses (similar to interim analysis of a randomized trial) powered for a 25

170 We conducted an unplanned interim analysis of a randomized, multicenter, open-labe

171 ata monitoring committee report of a planned interim analysis of a trial in second-line SQ NSCLC (CM0

172 We report the results of an interim analysis of a trial of rVSV-ZEBOV in Guinea, wes

173 This is a planned interim analysis of an on-going trial that will run for

174 A planned interim analysis of change in alanine aminotransferase a

175 This report focuses on a planned interim analysis of cognitive outcomes in 309 children a

176 l to cohort 2 was stopped after an unplanned interim analysis of cohort 1 and the statistical analysi

177 on for cohorts 5, 6, and 7 occurred after an interim analysis of data for cohorts 1 to 4.

178 An interim analysis of data from the HIV Prevention Trials

179 The interim analysis of OS (64% censored) demonstrated a 13%

180 An interim analysis of overall survival (38% maturity, mean

181 At the second interim analysis of overall survival (58% maturity), ove

182 We present data from the second interim analysis of overall survival and a retrospective

183 Interim analysis of overall survival favoured the pertuz

184 The interim analysis of overall survival showed a strong tre

185 An interim analysis of overall survival showed no significa

186 as specified in the protocol; a prespecified interim analysis of overall survival was conducted and i

187 In the planned interim analysis of overall survival, 14 deaths occurred

188 We report results from a preplanned second interim analysis of overall survival, which was planned

189 Data presented are from the planned primary interim analysis of part one of the study when all patie

190 y for futility based on results of a planned interim analysis of participants enrolled at least 5 yea

191 primary endpoint at the prespecified second interim analysis of progression-free survival in the int

192 The authors performed a preplanned interim analysis of results from 12,631 examinations int

193 If an interim analysis of such trials demonstrates compelling

194 Both studies were halted when an interim analysis of the AGENT-3 trial indicated that the

195 This is an interim analysis of the first 100 randomized patients.

196 On the basis of an interim analysis of the first 188 patients who completed

197 An interim analysis of the first 23 assessable patients in

198 eath ligand 1 (PD-L1) and report here on the interim analysis of the malignant pleural mesothelioma c

199 nts with early nodal metastases according to interim analysis of the Multicenter Selective Lymphadene

200 This interim analysis of the ongoing open-label EXTEND (Eltro

201 We report data from the interim analysis of the ongoing VIVIANE study, the aim o

202 Because interim analysis of the primary end point revealed an im

203 not enrolling participants; results for the interim analysis of the primary endpoint are presented.

204 A planned interim analysis of the primary outcome showed improved

205 at 1 year after the end of treatment, as an interim analysis of the REP 301-LTF trial (planned durat

206 Interim analysis of the results suggests the superiority

207 This trial is ongoing; here, we report an interim analysis of the SCLC cohort.

208 This report is a prespecified, 3-year interim analysis of the trial.

209 We report an interim analysis of this ongoing trial.

210 This report is the third interim analysis of this study.

211 An interim analysis of this trial is reported here.

212 The interim analysis of time to progression met specified cr

213 lyses and stopped the trial after the second interim analysis on Aug 3, 2013, as directed by the data

214 At the interim analysis on June 14, 2002, when the last patient

215 comparisons, which stopped accrual early at interim analysis on the basis of failure-free survival.

216 rior to phase 3 for treatment futility after interim analysis on the recommendations of an independen

217 After an interim analysis, open-label combination therapy with bo

218 risk for death from surgery according to an interim analysis, overall mortality in the surgery group

219 In this interim analysis, patients were assessed for the occurre

220 An interim analysis (performed after 15 subjects completed

221 Because of the interim-analysis plan, a P value of less than 0.044 at t

222 The interim analysis presented here was protocol-specified a

223 terminated for efficacy at the prespecified interim analysis, radium-223 improved overall survival.

224 of 513 patients were enrolled when a planned interim analysis recommended early closure for futility.

225 The trial is closed and this is the first interim analysis, reporting the objective response prima

226 This interim analysis reports outcomes of 60 patients with a

227 oints were measured through week 22, when an interim analysis resulted in early stopping of the plann

228 ung, and Blood Institute closed SWiTCH after interim analysis revealed equivalent liver iron content,

229 A second interim analysis revealed that a prespecified boundary f

230 roup and 78 in the placebo group), a planned interim analysis revealed that patients in the combinati

231 ed early on December 12, 2006, after a third interim analysis reviewed by the data and safety monitor

232 INTERPRETATION: The results of this interim analysis show that venetoclax has durable clinic

233 ments were unblinded in 2009, when a planned interim analysis showed a significantly longer time to d

234 The study was halted after a planned interim analysis showed a significantly worse 100-day su

235 Recruitment was stopped early when an interim analysis showed an increased rate of death at 36

236 data and safety monitoring board, after the interim analysis showed efficacy of hypothermia.

237 he Data Safety and Monitoring Board after an interim analysis showed futility in reaching the primary

238 The study was stopped after interim analysis showed higher mortality in the pyridoxa

239 d Kingdom had been enrolled in the trial, an interim analysis showed increased mortality at a correct

240 In December, 2010, an interim analysis showed lack of efficacy and the trial w

241 Interim analysis showed no overall survival benefit.

242 the trial was unblinded early when a planned interim analysis showed significantly longer time to tum

243 The trial was stopped early after an interim analysis showed that the failure rate of propran

244 A prespecified interim analysis showed that the rate of progression-fre

245 inated early on the basis of a pre-specified interim analysis showing superiority of niacin over ezet

246 men With Mammography-Negative Dense Breasts' interim analysis shows that ultrasound has better increm

247 Data were unblinded at the interim analysis, since these results exceeded the prepl

248 The study was discontinued following an interim analysis that found significant differences of r

249 At a prespecified interim analysis that included 1135 primary end-point ev

250 became apparent at the time of an unplanned interim analysis that MRI was detecting cases of hemorrh

251 The study was unblinded after a planned interim analysis that was performed after 43% of the exp

252 After an interim analysis the study was stopped because the crite

253 In the interim analysis, the change from baseline in the HAM-D

254 On May 15, 2015, on the basis of an interim analysis, the data and safety monitoring board d

255 At its first interim analysis, the Data Monitoring and Ethics Committ

256 At the third planned interim analysis, the futility boundary was crossed, and

257 At first interim analysis, the hazard ratio (HR) by independent r

258 At the second interim analysis, the hazard ratio for mortality in pati

259 At the time of the interim analysis, the median follow-up was 29.4 months (

260 At the time of a preplanned interim analysis, the primary efficacy analysis populati

261 At interim analysis, the primary end point was significantl

262 Following a second prespecified interim analysis, the study was stopped because of poten

263 At the first prespecified interim analysis, the study was stopped early on the rec

264 On the basis of the results of an interim analysis, the trial was stopped after a median f

265 A preplanned interim analysis to assess efficacy revealed inadequate

266 analysis after approximately 87 events (25% interim analysis) to assess a noninferiority HR of 2.0 f

267 utility boundary was crossed at a preplanned interim analysis, trial accrual terminated in April, 201

268 This is an interim analysis, up to Nov 1, 2012, when the trial was

269 Planned interim analysis using the O'Brien-Fleming boundary was

270 stopping boundary for futility at the first interim analysis was a p value of at least 0.68.

271 The otamixaban dose selected at interim analysis was an intravenous bolus of 0.080 mg/kg

272 A planned interim analysis was conducted at 69.8% of expected even

273 A planned interim analysis was conducted for otamixaban dose selec

274 An interim analysis was conducted in November, 2013, after

275 A preplanned interim analysis was conducted to identify the regimen t

276 The vaccine-associated risk seen in interim analysis was confirmed but waned with time from

277 The primary endpoint of this 6 month interim analysis was geometric mean titres (GMTs) of neu

278 The cutoff date for this prespecified interim analysis was Jan 3, 2017.

279 A preplanned interim analysis was performed at month 24, stratifying

280 A preplanned interim analysis was performed by an independent data an

281 A preplanned interim analysis was performed on January 29, 2016, afte

282 Preplanned interim analysis was performed on the first 120 patients

283 Interim analysis was performed when 221 patients died (1

284 r reports of early nonresponse, an unplanned interim analysis was performed.

285 One interim analysis was planned to allow the study to stop

286 An interim analysis was pre-planned after 500 patients achi

287 The primary endpoint of this interim analysis was the proportion of patients who lost

288 This prespecified interim analysis was to be conducted on the first 315 pa

289 The aim of this second interim analysis was to compare overall survival between

290 This study is ongoing; data for this interim analysis were collected per regulatory agencies'

291 ommittee interrupted enrollment at a planned interim analysis when outcomes crossed predetermined sto

292 me from randomisation measured at the second interim analysis, when the proportion of deaths had reac

293 At the interim analysis, which involved 809 patients, radium-22

294 Study was terminated prematurely after interim analysis, which showed no difference in overall

295 (24 HBO, 22 HBA) were analyzed at the second interim analysis, which was scheduled to take place when

296 Interim analysis will be performed once 123 patients are

297 Median PFS at the protocol prespecified interim analysis with 58 PFS events (primary end point)

298 y for lack of treatment effects at a planned interim analysis with 81 evaluable participants in the i

299 At the first planned interim analysis with half the events, the inferiority b

300 significantly improved with pertuzumab in an interim analysis without the median being reached.